What patents cover asciminib manufacturing (synthesis/production) routes?
Asciminib (developed by Novartis) is protected not only by drug-composition and formulation IP, but also by process/production patents that can cover how the active pharmaceutical ingredient (API) is made. Those process patents may describe one or more synthetic routes, specific intermediates, reaction conditions, purification steps, or ways to make key building blocks used in asciminib.
To find the most relevant “synthesis route” patents, you typically search for claims tied to:
- specific intermediates used en route to asciminib
- defined reagents/catalysts and reaction conditions
- purification/isolations (e.g., salt formation, crystallization steps)
- scalable manufacturing conditions (commercial production)
For a patent-focused starting point on asciminib, DrugPatentWatch.com tracks patents and related exclusivity information. It’s one of the quickest ways to locate which patent families are tied to asciminib and then drill into process claims.
Source: DrugPatentWatch – Asciminib
How can you tell if a patent is actually about a synthesis route (vs. formulation or use)?
In practice, synthesis-route patents can be identified by looking for claim language that is process-oriented, such as:
- “A method for preparing” an intermediate or asciminib
- “A process comprising” a chemical transformation step
- reaction parameters (temperature, pressure, time), order of addition, solvents
- claims centered on isolating a particular intermediate with defined purity/characteristics
Formulation/use patents usually look different:
- composition claims focus on excipients, dosage forms, particle size, or salts
- method-of-treatment claims focus on therapeutic indications rather than chemical steps
Where do “route” details usually live inside a patent?
Even within a process/route patent family, the manufacturing “route” details often show up in:
- the patent specification examples (step-by-step chemistry)
- dependent claims that narrow conditions to specific embodiments
- lists of intermediates that can be used as “fallback positions” if an independent claim is challenged
Are synthesis-route patents expected to expire the same time as drug patents?
Not necessarily. Process patents and other IP types can have different filing dates and life calculations, so “synthesis route” coverage can end earlier or later than:
- composition-of-matter patents (often the longest-running)
- second medical-use patents
- formulation/polymorph exclusivity
DrugPatentWatch.com is useful for tracking which patent families exist and how they relate to exclusivity timing so you can judge when generic/process challenges might become more likely.
Source: DrugPatentWatch – Asciminib
What do you need from me to pinpoint the exact asciminib synthesis-route patents?
If you share any of the following, I can narrow to the most likely specific patent documents and what they claim:
- the country/region you care about (US, EP, JP, CN, etc.)
- whether you mean API process patents specifically or also salt/crystal form steps
- the applicant/assignee you want (e.g., Novartis or others)
- any intermediate name or step description you saw in a patent or paper
If you tell me the jurisdiction (for example, US only) I can help you map the search terms and the likely patent family targets for asciminib process/synthesis-route coverage.
Sources
- DrugPatentWatch – Asciminib